Navigation Links
Axela introduces software to support 21 CFR Part 11 Compliance for Regulated Environments
Date:5/7/2009

TORONTO, May 7 /PRNewswire/ - Axela Inc., is pleased to announce the release of a software package for the dotLab(R) System that provides technical controls to support compliance with 21 CFR Part 11 regulations. This new package will be of particular interest to those working in pharmaceutical, biotech or other regulated environments. Features include a secure database, audit trails, electronic signature controls and user name/password controls.

"The dotLab System has proven its value in the rapid development of assays for monitoring protein production and biomarker quantitation. Axela is committed to further expanding the applications for our technology platform and increasing functionality" said Rocky Ganske, President and CEO, Axela Inc. "The new 21 CFR Part 11 Compliance Support Software simplifies implementation of controlled assays and provides dotLab System users with a flexible single platform for development, validation and transfer of assays between labs."

This new software is an integral component in Axela's suite of tools that significantly accelerate biomarker and assay development. Based on unique optics technology, the dotLab system allows reagent qualification, assay development and routine quantitative analysis to be combined into a single platform. panelPlus(TM) Sensors provide the industry's first real time, user configurable multiplex and have been designed to facilitate validation of both clinical utility and analytical performance. Panel constituents selected from a menu of established biomarkers can be freely combined with proprietary targets to allow direct comparison in a single sample. To further facilitate independent validation the same reagents are available in an orthogonal plate based EIA format. panelPlus Sensors are currently in use by Axela collaborators and will be commercially available this summer.

About Axela Inc.

Axela's products deliver rapid understanding of biological interactions, and use real time information to significantly improve the amount and quality of information derived from traditional immunoassay. This approach shortens time to result, greatly simplifies multiplexing and provides access to unique categories of markers that form a pipeline of future diagnostic offerings. Axela has operations in Toronto and California. Its major investor is VenGrowth Private Equity Partners Inc.


'/>"/>
SOURCE Axela Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senate Introduces Legislation to Increase Access to Physical Therapist Services
2. Howard Leight Introduces QuietDose(TM): In-Ear Dosimetry Measures Noise Exposure in Real-Time to Help Prevent Workplace Hearing Loss
3. Video: Jewelry Television(R) Introduces DermaGem(TM)
4. SignatureForum Introduces NewImageSpecialists.com
5. Microsoft Introduces Groundbreaking Technology for Life Sciences
6. Verathon(R) Introduces BladderScan(R) BVM 9500 Bladder Volume Instrument To Help Urologists Diagnose Bladder Dysfunction
7. Working Towards Counting Malaria Out Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance
8. AdEx Media Introduces RezActiv(TM)
9. Chill Cooling Towels Introduces Instant Relief for Hot Flashes and Night Sweats
10. PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments
11. Lumenis Introduces the HoLEP Simulator and the PolyScope Disposable Ureteroscope at American Urology Association 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal Laboratory Consortium ... . The site houses a wealth of federal resources that businesses can leverage ... called technology transfer (T2). As a network of over 300 federal laboratories, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... A man who has struggled to quit smoking, a man ... , was determined to find solutions to his problems – and he did. Now Nabat, ... is ready to introduce his breakthrough inventions to the world and better people's lives. His ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a full ... beneficiary of their ongoing community enrichment program. The current campaign fundraises for Angels ... are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from ... a cluster of melanin when exposed to sunlight. Although most moles are benign and ... embarrassment. Historically, mole removal has involved a painful, often expensive visit to ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... February 8, 2016 ... published by Allied Market Research titled, "World ... Forecasts, 2014-2020", estimates the world synthetic biology market ... and sequencing technology segment would continue to lead ... tools segment, collectively, held around half of the ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology: